Press release
ESR1 Mutated Metastatic Breast Cancer Market Size in the 7MM is ~USD 1,300 Million in 2023 and is expected to grow a significant CAGR by 2034, estimates DelveInsight
Discover Key Insights into the ESR1 Mutated Metastatic Breast Cancer Market with DelveInsight's In-Depth Report @ ESR1 Mutated Metastatic Breast Cancer Market Size [https://www.delveinsight.com/sample-request/esr1-mutated-metastatic-breast-cancer-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Key Takeaways from the ESR1 Mutated Metastatic Breast Cancer Market Report
* In February 2025:- Sermonix Pharmaceuticals Inc.:- This is an open-label, multicenter, single-arm safety study evaluating the safety and tolerability of the lasofoxifene and abemaciclib combination for the treatment of pre- and postmenopausal women with locally advanced or metastatic ER+/HER2- breast cancer who have disease progression on first and/or 2nd lines of hormonal treatment for metastatic disease and have an ESR1 mutation.
* The total diagnosed prevalent cases of ESR1-mutated Metastatic Breast Cancer in the United States was around 18,800 cases in 2023.
* The diagnosed prevalent cases of ESR1-mutated HR+ Metastatic Breast Cancer on first-line of treatment in the United States was estimated to be around 18,400 in 2023.
* Among the EU4 countries, Germany had the highest cases of ESR1 mutation in metastatic breast cancer, followed by France, whereas Spain accounted for the lowest number of cases in 2023.
* According to DelveInsight estimates, Japan reported approximately 45,000 cases of metastatic breast cancer, equivalent to around 13% of total cases in the 7MM.
* The leading Esr1-mutated Metastatic Breast Cancer Companies such as AstraZeneca, Olema Pharmaceuticals, Arvinas, Sermonix Pharmaceuticals, Roche, Eli Lilly and Company, H3 Biomedicine, Eisai, Pfizer, Sun Pharma Advanced Research Company, Zenopharm , and others
* Promising Esr1-mutated Metastatic Breast Cancer Therapies such as Elacestrant (RAD1901), Ibrance (Palbociclib), Rintodestrant (G1T48), SCO-120, ZB716, ARV-471, Lasofoxifene, H3B-6545, Giredestrant (RG6171, GDC-9545), Camizestrant (AZD9833), ZN-c5, OP1250 , and others
Stay ahead in the ESR1 Mutated Metastatic Breast Cancer Therapeutics Market with DelveInsight's Strategic Report @ ESR1 Mutated Metastatic Breast Cancer Market Outlook [https://www.delveinsight.com/sample-request/esr1-mutated-metastatic-breast-cancer-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Esr1-mutated Metastatic Breast Cancer Epidemiology Segmentation
* Total Diagnosed Prevalent Cases of HR-Positive Breast Cancer
* Stage-specific Diagnosed Prevalent Cases of HR-positive Breast Cancer
* Total Diagnosed Prevalent Cases of Metastatic Breast Cancer
* Diagnosed Prevalent Cases of ESR1 Mutated Metastatic Breast Cancer
* Line-wise treatable cases of ESR1 Mutated Metastatic Breast Cancer
Download the report to understand which factors are driving ESR1 Mutated Metastatic Breast Cancer epidemiology trends @ ESR1 Mutated Metastatic Breast Cancer Prevalence [https://www.delveinsight.com/sample-request/esr1-mutated-metastatic-breast-cancer-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
ESR1 Mutated Metastatic Breast Cancer Marketed Drugs
* ORSERDU (elacestrant): Stemline Therapeutics (a wholly owned subsidiary of the Menarini Group)
ORSERDU (elacestrant) is a selective estrogen receptor degrader (SERD) out-licensed to Menarini Group. In January 2023, the US FDA approved ORSERDU for treating postmenopausal women or adult men with ER+, HER2, ESR1-mutated, advanced or metastatic breast cancer with disease progression following at least one line of endocrine therapy. Later in September 2023, the drug also got approved in Europe.
ESR1 Mutated Metastatic Breast Cancer Emerging Drugs
* Camizestrant (AZD9833): AstraZeneca
Camizestrant (AZD9833) is an oral SERD that has shown antitumor efficacy in a range of preclinical models of breast cancer. In June 2020, AstraZeneca initiated a Phase III clinical trial, SERENA-6, to evaluate the Safety and Efficacy of AZD9833 in combination with a CDK4/6 inhibitor (palbociclib or abemaciclib) for the treatment of patients with HR+ HER2 metastatic breast cancer with a detectable ESR1 mutation. As per Astrazeneca's pipeline, Camizestrant's + CDK4/6 inhibitor's estimated filing acceptance in 1st line HR+ HER2- ESR1m breast cancer is 2025. Apart from that, the indication for SERENA-6 has been granted Fast Track Designation (FTD) by the US FDA.
* Lasofoxifene: Sermonix Pharmaceuticals
Lasofoxifene is being investigated as a potent, bioavailable selective estrogen receptor modulator (SERM) with a differentiated safety profile that could prove useful in treating postmenopausal women and premenopausal women on ovarian suppression with locally advanced or metastatic ER+ breast cancer. Lasofoxifene's bioavailability and activity in estrogen receptor mutations could hold promise for patients who have acquired endocrine resistance due to ESR1 mutations, a common finding in the metastatic setting and an area of high unmet medical needs need.
Get In-Depth Knowledge on ESR1 Mutated Metastatic Breast Cancer Market Trends and Forecasts with DelveInsight @ ESR1 Mutated Metastatic Breast Cancer Treatment Market [https://www.delveinsight.com/sample-request/esr1-mutated-metastatic-breast-cancer-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
ESR1 Mutated Metastatic Breast Cancer Drugs Market Insights
The existing ESR1 treatment is mainly dominated by classes such as aromatase inhibitors, aromatase inhibitors + CDK4/6 inhibitors, and CDK4/6 + SERDs. For postmenopausal women with HR-positive, HER2-positive recurrent/Stage IV breast cancer, the preferred options available include fulvestrant with a CDK 4/6 inhibitor (palbociclib, ribociclib, and abemaciclib; category 1) or for those with tumor PIK3CA mutations, fulvestrant with alpelisib; everolimus with either an AI, tamoxifen or fulvestrant; monotherapy with fulvestrant, nonsteroidal or steroidal AI, or SERM.
ESR1-mutated Metastatic Breast Cancer Market Outlook
ESR1 mutations have increased, even with aromatase inhibitor (AI) therapy, indicating their adaptability to AI therapeutic conditions. In addition, the presence of ESR1 mutations has been correlated with a shorter time to treatment failure, as metastatic breast cancer (MBC) patients with ESR1 mutations exhibit an inadequate response to and shorter duration of effective endocrine control. Suppose AI treatment provides selection pressure for mutant-bearing clonal outgrowth in patients.
Get In-Depth Knowledge on ESR1 Mutated Metastatic Breast Cancer Market Trends and Forecasts with DelveInsight @ ESR1 Mutated Metastatic Breast Cancer Treatment Market [https://www.delveinsight.com/sample-request/esr1-mutated-metastatic-breast-cancer-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Esr1-mutated Metastatic Breast Cancer Therapies and Key Companies
* Elacestrant (RAD1901): Radius Pharmaceuticals/Berlin-Chemie (Menarini Group)
* Ibrance (Palbociclib): Pfizer
* Rintodestrant (G1T48): G1 Therapeutics, Inc.
* SCO-120: Sun Pharma Advanced Research Company
* ZB716: Zenopharm
* ARV-471: Arvinas
* Lasofoxifene: Sermonix Pharmaceuticals
* H3B-6545: H3 Biomedicine/Eisai
* Giredestrant (RG6171, GDC-9545): Roche
* Camizestrant (AZD9833): AstraZeneca
* ZN-c5: Zentalis Pharmaceuticals
* OP1250: Olema Pharmaceuticals
Scope of the ESR1 Mutated Metastatic Breast Cancer Market Report
* Study Period: 2020-2034
* Coverage: 7MM
* Esr1-mutated Metastatic Breast Cancer Companies- AstraZeneca, Olema Pharmaceuticals, Arvinas, Sermonix Pharmaceuticals, Roche, Eli Lilly and Company, H3 Biomedicine, Eisai, Pfizer, Sun Pharma Advanced Research Company, Zenopharm , and others
* Esr1-mutated Metastatic Breast Cancer Therapies- Elacestrant (RAD1901), Ibrance (Palbociclib), Rintodestrant (G1T48), SCO-120, ZB716, ARV-471, Lasofoxifene, H3B-6545, Giredestrant (RG6171, GDC-9545), Camizestrant (AZD9833), ZN-c5, OP1250, and others
* Esr1-mutated Metastatic Breast Cancer Therapeutic Assessment: - Esr1-mutated Metastatic Breast Cancer current marketed and Esr1-mutated Metastatic Breast Cancer emerging therapies
* Esr1-mutated Metastatic Breast Cancer Market Dynamics: Esr1-mutated Metastatic Breast Cancer market drivers and Esr1-mutated Metastatic Breast Cancer market barriers
* Esr1-mutated Metastatic Breast Cancer Unmet Needs, KOL's views, Analyst's views, Esr1-mutated Metastatic Breast Cancer Market Access and Reimbursement
Table of Content
1 Key Insights
2 Report Introduction
3 Executive Summary
4 Key Events
5 Epidemiology and Market Forecast Methodology
6 ESR1-Mutated Metastatic Breast Cancer Market Overview at a Glance in the 7MM
7 Disease Background and Overview
8 Epidemiology and patient Population of the 7MM
9 Patient Journey
10 Key Endpoints in ESR1-mutated Metastatic Breast Cancer
11 Key Cross Competition of Drugs
12 Marketed Drug
13 Emerging Drugs
14 ESR1-mutated Metastatic Breast Cancer: The 7MM Market Analysis
15 Unmet Needs
16 SWOT Analysis
17 KOL Views
17.1 KOL Interviews
18 Market Access and Reimbursement
19 Appendix
20 DelveInsight Capabilities
21 Disclaimer
22 About DelveInsight
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=esr1-mutated-metastatic-breast-cancer-market-size-in-the-7mm-is-usd-1300-million-in-2023-and-is-expected-to-grow-a-significant-cagr-by-2034-estimates-delveinsight]
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/wolman-disease-market
Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release ESR1 Mutated Metastatic Breast Cancer Market Size in the 7MM is ~USD 1,300 Million in 2023 and is expected to grow a significant CAGR by 2034, estimates DelveInsight here
News-ID: 3883985 • Views: …
More Releases from ABNewswire
Anaplastic Thyroid Cancer Pipeline 2025: Innovative Clinical Developments by 8+ …
DelveInsight's, "Anaplastic Thyroid Cancer - Pipeline Insight, 2025," report provides comprehensive insights about 8+ companies and 8+ pipeline drugs in Anaplastic Thyroid Cancer pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
With anaplastic thyroid cancer increasingly prevalent worldwide and…
Cabinets 4 Less Scottsdale Showroom Offers Affordable Cabinetry Solutions
Cabinets 4 Less Scottsdale, a premier cabinet store located at 8445 E. McDonald Dr. in Scottsdale, AZ, is expanding its showroom to offer homeowners, contractors, and designers affordable, high-quality cabinetry. With a wide selection of styles and finishes, personalized consultations, and reliable service, the store provides cost-effective solutions for remodeling and construction projects in Scottsdale's growing housing market.
SCOTTSDALE, AZ - September 30, 2025 - Cabinets 4 Less Scottsdale [https://cabinets4lessscottsdale.com], a…
Hypercholesterolemia Pipeline 2025: Innovative Clinical Advancements by 25+ Glob …
DelveInsight's, "Hypercholesterolemia- Pipeline Insight, 2025" report provides comprehensive insights about 25+ companies and 30+ pipeline drugs in Hypercholesterolemia pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
With hypercholesterolemia reaching global epidemic proportions and contributing to comorbid conditions such as…
Anaplastic Large Cell Lymphoma Pipeline 2025: Innovative Clinical Developments b …
DelveInsight's, "Anaplastic Large Cell Lymphoma - Pipeline Insight, 2025," report provides comprehensive insights about 4+ companies and 4+ pipeline drugs in Anaplastic Large Cell Lymphoma pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
With anaplastic large cell lymphoma (ALCL)…
More Releases for Breast
Breast Health Monitoring App Market to Witness a Pronounce Growth during 2024-20 …
The latest market intelligence report published by WMR with the title "Global Breast Health Monitoring App Market 2024, Growth Opportunities, and Forecast" provides actionable insights on Healthcare and Pharmaceuticals industry. The report provides demand analysis, industry insights, competitive intelligence, and customer database.
The Research report on Breast Health Monitoring App Market presents a complete judgment of the market through strategic insights on future trends, growth factors, supplier landscape, demand landscape, Y-o-Y…
Primary Breast Cancer Survivor Phil Alderson Shines Light on Male Breast Cancer …
FOR IMMEDIATE RELEASE
Primary Breast Cancer Survivor Phil Alderson Shines Light on Male Breast Cancer During Breast Cancer Awareness Month
Liverpool, UK - October, 2023 - Phil Alderson, a primary survivor of male breast cancer, is taking bold steps this Breast Cancer Awareness Month to raise awareness of this often overlooked aspect of the disease. With a homemade cardboard sign that reads "Check Your Pecks," Phil has taken to the streets of…
Breast Health Monitoring App Market Recent Trends, In-depth Analysis, Size, and …
According to The Worldwide Market Reports, the Latest research report on "Breast Health Monitoring App Market Size, Revenue, Global Analysis, and Forecast 2023 to 2030" The Breast Health Monitoring App Market research study is a professional report with premium insights into the size of the business, current patterns, drivers, risks, potential outcomes, and major segments. The Industry Report forecasts the future growth of the market based on precise assumptions. Furthermore,…
Breast Pumps Market - Nurturing Convenience: Revolutionizing Breast Pump Technol …
Newark, New Castle, USA - new report, titled Breast Pumps Market The report has been put together using primary and secondary research methodologies, which offer an accurate and precise understanding of the Breast Pumps market. Analysts have used a top-down and bottom-up approach to evaluate the segments and provide a fair assessment of their impact on the global Breast Pumps market. The report offers an overview of the market, which…
Breast Imaging Market by Breast Ultrasound, Breast MRI, Automated Whole-Breast U …
Growth of breast imaging market driven by factors like rising incidence of breast cancer globally, growing government investments and funding for breast cancer treatment and related research, increasing awareness about early detection of breast cancer, rising geriatric population, technological advancements in breast imaging modalities, and launch of advanced breast imaging systems capable of detecting cancer in women with dense breast tissues.
Download Free PDF Brochure on Brest Imaging Market Report Now…
Breast Implants Market Report 2018: Segmentation by Product (Silicone Breast Imp …
Global Breast Implants market research report provides company profile for Allergan, Mentor Worldwide LLC, Hans biomed, Establishment Labs, Polytech Health & Aesthetics, Sientra, Inc., GC Aesthetics, Cereplas and Others.
This market study includes data about consumer perspective, comprehensive analysis, statistics, market share, company performances (Stocks), historical analysis 2012 to 2017, market forecast 2018 to 2025 in terms of volume, revenue, YOY growth rate, and CAGR for the year 2018 to…
